Background {#Sec1}
==========

It is well established that postoperative pulmonary complications (PPCs), especially postoperative respiratory failure, add greatly to perioperative morbidity and mortality, as well as to postoperative length of hospital stay \[[@CR1]--[@CR3]\]. Several independent risk factors for the development of PPCs have been identified, ranging from a patient's health conditions to surgical approaches and anesthetic management \[[@CR4]\]. Considering that more than 234 million surgical procedures are performed worldwide per year \[[@CR5]\], a reduction of the rate of PPCs might have an important impact on global morbidity and mortality and reduce health system costs. Anesthetists could importantly contribute to preventing such respiratory complications, such as through intraoperative mechanical ventilation strategies expected to affect PPCs beyond preoperative patient status optimization and selection of operative methods to minimize surgical trauma. In fact, mechanical ventilation during general anesthesia has the potential to cause harm to previously noninjured lungs \[[@CR4]\].

Authors of an individual patient data meta-analysis showed that intraoperative lung-protective mechanical ventilation using lower tidal volume (V~T~) in the range of 6 to 8 ml/kg of predicted body weight (PBW), with or without higher levels of positive end-expiratory pressure (PEEP) and with or without lung recruitment maneuvers (RMs), reduced the incidence of PPCs \[[@CR2]\]. More recently, authors of another individual patient data meta-analysis identified the use of intraoperative low V~T~ as a protective measure against PPCs, whereas the role of PEEP was unclear \[[@CR6]\]. In fact, in a randomized controlled trial with patients with body mass index (BMI) \<40 kg/m^2^ undergoing open abdominal surgery, higher PEEP with RMs did not prevent PPCs compared with lower PEEP without RMs \[[@CR7]\].

BMI is an important determinant of respiratory function before and during anesthesia in obese patients \[[@CR8]--[@CR10]\]. In these patients, lung function impairment can manifest as (1) reduced lung volume with increased atelectasis and/or small airway closure; (2) derangements in respiratory system, lung, and chest wall compliance as well as increased resistance; and (3) moderate to severe hypoxemia. These physiological alterations are more marked in obese patients with hypercapnia or obstructive sleep apnea (OSA). To reduce such complications, PEEP levels should theoretically be set higher in obese than in nonobese patients. However, there is as yet no clinical evidence supporting such an approach. An observational study conducted in 28 centers in France revealed that most patients undergoing general surgery, including obese patients, were ventilated with low PEEP (≤4 cmH~2~O) or even without PEEP, even though average PEEP was higher in obese than in nonobese patients \[[@CR11]\]. In fact, current recommendations on the use of PEEP and RMs \[[@CR4], [@CR12]\] are derived from trials that included mainly patients with BMI \<35 kg/m^2^ and therefore cannot be extrapolated to obese patients.

The aim of the PRotective Ventilation with Higher versus Lower PEEP during General Anesthesia for Surgery in OBESE Patients (PROBESE) trial is to compare the effects of two intraoperative mechanical ventilation strategies on PPCs, extrapulmonary postoperative complications (PEPCs), and length of hospital stay, as well as intraoperative lung function and hemodynamics, in surgical patients with BMI ≥35 kg/m^2^. We hypothesized that intraoperative mechanical ventilation using high PEEP with periodic RMs, as compared with low PEEP without RMs, prevents PPCs in obese patients.

Methods/design {#Sec2}
==============

Objectives and design {#Sec3}
---------------------

PROBESE is a prospective international multicenter, randomized, controlled, two-arm trial initiated by investigators of the PROtective VEntilation NETwork ([www.provenet.eu](http://www.provenet.eu)). In total, 2013 patients will be randomly assigned to one of two different intraoperative mechanical ventilation strategies (*see* Consolidated Standards of Reporting Trials \[CONSORT\] diagram, Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Consolidated Standards of Reporting Trials (CONSORT) diagram for the PRotective Ventilation with Higher versus Lower PEEP during General Anesthesia for Surgery in OBESE Patients (PROBESE) trial. *PEEP* Positive end-expiratory pressure

The PROBESE trial will test the hypothesis that, during an intraoperative lung-protective mechanical ventilation strategy with low V~T~ s, higher levels of PEEP and RMs, as compared with ventilation with lower levels of PEEP without RMs, reduce PPCs in obese patients at intermediate to severe risk for PPCs. After starting the trial, recalculation of the sample size was conducted upon a recommendation of the Data and Safety Monitoring Board (DSMB) (*see* "[Sample size calculations](#Sec16){ref-type="sec"}" section). There were changes in neither the study protocol (version 2.5; February 2016, Additional file [1](#MOESM1){ref-type="media"}) nor any of the endpoints. A complete checklist of recommended items to address in a clinical trial protocol and related documents according to the \"Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 is provided in Additional file [2](#MOESM2){ref-type="media"}.

Study population {#Sec4}
----------------

Investigators screen for obese patients with BMI ≥35 kg/m^2^ scheduled for surgery under general anesthesia. Patients are eligible if the expected duration of surgery (from incision to closure) exceeds 2 h and if they are at intermediate to high risk for PPCs. The number of patients meeting these enrollment criteria will be recorded.

To identify patients at risk for PPCs, the Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score is used \[[@CR13]\]. This score predicts individual preoperative risk for PPCs using seven independent predictors, four of which are patient-related and three of which are surgery-related (Table [1](#Tab1){ref-type="table"}). An ARISCAT risk score ≥26 is associated with an intermediate to high risk for PPCs.Table 1Assess Respiratory Risk in Surgical Patients in Catalonia scoresMultivariate analysis, OR (95% CI), *n* = 1624β CoefficientRisk score^a^Age, years ≤501 51--801.4 (0.6--3.3)0.3313 \>805.1 (1.9--13.3)1.61916Preoperative SpO~2~, % ≥961 91--952.2 (1.2--4.2)0.8028 ≤9010.7 (4.1--28.1)2.37524Respiratory infection in the last month5.5 (2.6--11.5)1.69817Preoperative anemia (≤10 g/dl)3.0 (1.4--6.5)1.10511Surgical incision Peripheral1 Upper abdominal4.4 (2.3--8.5)1.48015 Intrathoracic11.4 (4.9--26.0)2.43124Duration of surgery, h ≤21 \>2--34.9 (2.4--10.1)1.59316 \>39.7 (4.7--19.9)2.26823Emergency procedure2.2 (1.04--4.5)0.7688*SpO* ~*2*~ Peripheral oxyhemoglobin saturation measured by pulse oximetry breathing air in supine positionIndependent predictors of risk for development of postoperative pulmonary complications as described by Canet et al. \[[@CR13]\] (ARISCAT score). A risk score ≥26 predicts an intermediate to high risk for postoperative pulmonary complications)^a^The simplified risk score is the sum of each logistic regression coefficient multiplied by 10, after rounding off its value

Patients are excluded from participation if they are aged \<18 years, have undergone any kind of previous lung surgery, have been invasively mechanically ventilated for longer than 30 minutes within the last 30 days before surgery, or have received recent immunosuppressive medication (chemotherapy or radiation therapy up to 2 months prior to surgery). Further exclusion criteria comprise neurosurgical procedures and cardiac surgery, need for one-lung ventilation or planned reintubation following surgery, need for intraoperative prone or lateral decubitus position, enrollment in another interventional study, or refusal to give written informed consent. Additionally, patients showing at least one the following medical conditions are excluded: pregnancy (excluded by anamnesis and/or laboratory analysis), persistent hemodynamic instability or intractable shock (considered hemodynamically unsuitable for the study by the patient's managing physician), history of severe chronic obstructive pulmonary disease (COPD; defined as noninvasive ventilation and/or oxygen therapy at home or repeated systemic corticosteroid therapy for acute exacerbations of COPD), severe cardiac disease (defined as New York Heart Association class III or IV, acute coronary syndrome, or persistent ventricular tachyarrhythmia), concurrent acute respiratory distress syndrome (ARDS) expected to require prolonged postoperative mechanical ventilation, severe pulmonary arterial hypertension (defined as systolic pulmonary arterial pressure \>40 mmHg), intracranial injury, or tumor or neuromuscular disease.

Intervention {#Sec5}
------------

Patients undergo intraoperative lung-protective mechanical ventilation with protective low V~T~ of 7 ml/kg (PBW), and they are randomly assigned to a PEEP level of 12 cmH~2~O with planned lung RMs performed after intubation, hourly thereafter and preceding extubation ("high PEEP"), or a level of PEEP of 4 cmH~2~O without planned RMs ("low PEEP"). PEEP levels are to be maintained throughout the whole period of intraoperative mechanical ventilation.

Minimization of bias {#Sec6}
--------------------

The allocation sequence is computer-generated (nQuery 4; Statsols, Boston, MA, USA) using permuted blocks of different block sizes, with a maximum block size of 8. Allocation is stratified per center with an allocation ratio of 1:1 for each group. The process of sequence generation and storage is managed by an independent information technology expert not involved in patient care. Randomization is then performed patient-by-patient using a web interface as an integral part of the online case report form (CRF, Additional file [3](#MOESM3){ref-type="media"}; *see* "[Handling of data](#Sec15){ref-type="sec"}" section).

At each study site, at least two investigators are involved with the study. One investigator is involved with the intraoperative mechanical ventilation strategy and performs the interventions defined in the protocol. A second investigator, who is blinded to randomization, performs postoperative visits and assessment of primary and secondary endpoints.

Standard procedures {#Sec7}
-------------------

To avoid interference with the trial intervention, routine elements of perioperative anesthetic care (including general anesthesia, postoperative pain management, physiotherapeutic procedures, and fluid management) are performed according to each center's specific expertise and clinical routine. The following approaches are suggested (not mandatory) for anesthetic management:Use of inhalational isoflurane, desflurane, or sevoflurane; intravenous propofol, remifentanil, or sufentanil; and cisatracurium, atracurium, vecuronium, or rocuronium as required;Use of a balanced solution of prostigmine, or neostigmine and atropine or glycopyrrolate, for reversal of muscle relaxation, guided by neuromuscular function monitoring;Performing postoperative pain management to achieve a visual analogue scale (VAS) pain score \<3, and regional or neuraxial analgesia should be used whenever indicated;Use of physiotherapy by early mobilization, deep breathing exercises with and without incentive spirometry, and stimulation of cough in the postoperative period; (5) avoidance of hypo- and hypervolemia;Use of invasive measurement of arterial blood pressure whenever indicated; andUse of appropriate prophylactic antibiotic drugs whenever indicated.

Data on the procedures applied will be collected in detail and analyzed.

In addition, the study protocol stresses that routine intraoperative monitoring should include measurements of noninvasive blood pressure, pulse oximetry, end-tidal carbon dioxide fraction, and electrocardiography. Every patient should receive at least one peripheral venous line to allow adequate fluid resuscitation during the study period. Nasogastric tubes, urinary bladder catheters, and/or other intravenous catheters, as well as other, more invasive monitoring, may be used according to local practice and/or guidelines. Other procedures should follow the Safe Surgery Checklist of the World Health Organization (WHO) ([www.who.int/patientsafety/safesurgery/en/index.html](http://www.who.int/patientsafety/safesurgery/en/index.html)).

Mechanical ventilation {#Sec8}
----------------------

Mechanical ventilation is performed with anesthesia ventilators in use at each individual center participating in the study. Patients undergo volume-controlled mechanical ventilation with the lowest possible fraction of inspired oxygen (FiO~2~; ≥0.4) to maintain a peripheral oxyhemoglobin saturation measured by pulse oximetry (SpO~2~) \>92%, an inspiratory-to-expiratory ratio (I:E) of 1:2, and a respiratory rate adjusted to normocapnia (end-tidal carbon dioxide partial pressure between 35 and 45 mmHg). It is left to the discretion of the attending anesthesiologist whether to use a higher FiO~2~.

V~T~ is set to 7 ml/kg (PBW). The PBW is calculated according to a predefined formula: 50 + 0.91 × (centimeters of height − 152.4) for men and 45.5 + 0.91 × (centimeters of height − 152.4) for women \[[@CR14], [@CR15]\]. V~T~ throughout this protocol refers to the actual inspired V~T~ in the ventilator circuit. PEEP is set according to the randomized intervention to 4 vs. 12 cmH~2~O and is modified only as part of the rescue strategy (in case of desaturation; *see* below) or at the discretion of the treating physician.

Planned and unplanned recruitment maneuvers {#Sec9}
-------------------------------------------

The RM, as part of the high-PEEP strategy, is performed directly after induction of anesthesia, after any disconnection from the mechanical ventilator, every 1 h during surgery, and before extubation, in a hemodynamically stable situation as judged by the anesthesiologist. RMs may also be performed as part of a rescue strategy in the low-PEEP group. To obtain standardization among centers, RMs will be performed in volume-controlled ventilation mode, as shown schematically in Fig. [2](#Fig2){ref-type="fig"}, and according to the following steps:Fig. 2Lung recruitment maneuver protocol. *Ppeak* Peak airway pressure, *Pplat* Plateau airway pressure, *PEEP* Positive end-expiratory pressure, *Vt* Tidal volume normalized for predicted body weight, *RR* Respiratory rate, *I:E* Ratio between inspiratory and expiratory time Set peak inspiratory pressure limit to 55 cmH~2~O.Set V~T~ to 7 ml/kg PBW and respiratory rate to ≥6 breaths/minute while PEEP is 12 cmH~2~O (or higher if during rescue; *see* below).Set I:E to 1:1.Increase V~T~ in steps of 4 ml/kg PBW until plateau pressure reaches 40--50 cmH~2~O.If the maximum V~T~ allowed by the anesthesia ventilator is achieved and the plateau pressure is \<40 cmH~2~O, increase the PEEP as needed but only to a maximum of 20 cmH~2~O.Allow the patient three breaths while maintaining plateau pressure of 40--50 cmH~2~O.Set respiratory rate, I:E, inspiratory pause, and V~T~ back to prerecruitment values while maintaining PEEP at 12 cmH~2~O (or higher if during rescue).

Rescue strategies for intraoperative hypoxemia {#Sec10}
----------------------------------------------

If SpO~2~ ≤92% develops, increase in airway resistance, presence of intrinsic PEEP, hemodynamic impairment, and ventilator malfunction must be excluded before group-specific stepwise rescue strategies can be applied (Table [2](#Tab2){ref-type="table"}).Table 2Rescue strategies for intraoperative hypoxemiaLower PEEPHigher PEEPStepFiO~2~PEEP (cmH~2~O)FiO~2~PEEP (cmH~2~O)10.540.414(+RM)20.640.416(+RM)30.740.418(+RM)40.840.51850.940.61861.040.71871.050.81881.060.91891.07(+RM)1.018101.020(+RM)*Abbreviations: FiO* ~*2*~ Fraction of inspired oxygen, *PEEP* Positive end-expiratory pressure, *RM* Recruitment maneuverIf intraoperative hypoxemia, defined as oxygen saturation ≤92%, develops, sequences of interventions will be used according to group assignment

In patients receiving lower PEEP levels, rescue consists primarily of an increase in FiO~2~, whereas elevation of PEEP levels is restricted to more severe cases of hypoxemia. In the higher PEEP group, the rescue strategy consists primarily of increase of PEEP before FiO~2~ is to be increased. At any rescue step, the treating physician may consider reducing PEEP if SpO~2~ deteriorates further in an otherwise hemodynamically stable patient.

Protocol deviation {#Sec11}
------------------

Anesthesiologists may deviate from the ventilation protocol at any time if concerns about patient safety arise or upon the surgeon's request. PEEP may be modified according to the anesthesiologist's judgment in the presence of any of the following clinical situations:Decrease in systolic arterial pressure \<90 mmHg and unresponsive to fluids and/or vasoactive drugsNeed for a dosage of vasoactive drugs at the tolerance limitNew arrhythmias unresponsive to the treatment suggested by the Advanced Cardiac Life Support Guidelines \[[@CR16]\]Blood loss requiring massive transfusion (defined as replacement of \>100% blood volume in 24 h or \>50% of blood volume in 4 h to maintain hematocrit \>21% \[hemoglobin \>7 mg/dl\])Any life-threatening surgical complication that might benefit from changes in PEEP

Details about any protocol deviation will be prospectively collected and analyzed.

Study endpoints {#Sec12}
---------------

The primary endpoint of PROBESE is a collapsed composite of all PPCs developing within the first 5 postoperative days. With this approach, each complication is weighted equally. Patients who develop a least one complication are considered as meeting the primary endpoint.

PPCs are defined as follows:Mild respiratory failure (partial pressure of arterial oxygen \[PaO~2~\] \<60 mmHg or SpO~2~ \<90% breathing at least 10 minutes of room air but responding to supplemental oxygen of 2 L/minute, excluding hypoventilation);Moderate respiratory failure (PaO~2~ \<60 mmHg or SpO~2~ \<90% breathing ≥10 minutes of room air but responding only to supplemental oxygen \>2 L/minute, excluding hypoventilation);Severe respiratory failure (need for noninvasive or invasive mechanical ventilation, excluding hypoventilation resulting from use of sedative agents);ARDS (according to the Berlin Definition \[[@CR17]\]);Bronchospasm (newly detected expiratory wheezing treated with bronchodilators);New pulmonary infiltrates (chest x-ray demonstrating new monolateral or bilateral infiltrate without other clinical signs);Pulmonary infection (new or progressive radiographic infiltrate plus at least two of the following: antibiotic treatment, tympanic temperature \>38 °C, leukocytosis or leukopenia \[white blood cell count \<4000 cells/mm^3^ or \>12,000 cells/mm^3^\], and/or purulent secretions);Aspiration pneumonitis (respiratory failure after the inhalation of regurgitated gastric contents);Pleural effusion (chest x-ray demonstrating blunting of the costophrenic angle, loss of the sharp silhouette of the ipsilateral hemidiaphragm in upright position, evidence of displacement of adjacent anatomical structures, or \[in supine position\] a hazy opacity in one hemithorax with preserved vascular shadows);Atelectasis (lung opacification with shift of the mediastinum, hilum, or hemidiaphragm toward the affected area, as well as compensatory overinflation in the adjacent nonatelectatic lung);Cardiopulmonary edema (clinical signs of congestion, including dyspnea, edema, rales, and jugular venous distention, with chest x-ray demonstrating increase in vascular markings and diffuse alveolar interstitial infiltrates); andPneumothorax (air in the pleural space with no vascular bed surrounding the visceral pleura).

Secondary clinical endpoints include the following:Collapsed severe PPC composite, defined as any of the above-mentioned adverse pulmonary events, except mild respiratory failure;Intraoperative adverse events (AEs), such as hypoxemia (defined as SpO~2~ ≤92%), hypotension (defined as systolic blood pressure \<90 mmHg), and bradycardia (defined as heart rate \<50 beats/minute);Unexpected need for intensive care unit (ICU) admission or ICU readmission;Hospital-free days at follow-up day 90;Postoperative wound healing; andPostoperative extrapulmonary complications (PEPCs).

PEPCs include systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock (all according to consensus criteria \[[@CR18]\]); extrapulmonary infection (wound infection or any other infection); coma (Glasgow Coma Scale score \<8 in the absence of therapeutic coma or sedation); acute myocardial infarction (according to universal definition of myocardial infarction \[[@CR19]\]); acute renal failure (according to the risk, injury, failure, loss, end-stage kidney disease \[RIFLE\] classification system \[[@CR20]\]); disseminated intravascular coagulation (DIC) (according to the International Society of Thrombosis and Hemostasis diagnostic scoring system for DIC \[[@CR21]\]); gastrointestinal failure (GIF) (defined according to the GIF score \[[@CR22]\]); and hepatic failure (defined as the ratio of total bilirubin on postoperative day 5 to postoperative day 1 \>1.7 and ratio of international normalized ratio \[INR\] on postoperative day 5 to postoperative day 1 \>1.0, or new presence of hepatic encephalopathy and coagulopathy \[INR \>1.5\] within 8 weeks after initial signs of liver injury \[e.g., jaundice\] without evidence of chronic liver disease) (adapted from Du et al. \[[@CR23]\] and Wlodzimirow et al. \[[@CR24]\]).

At the discretion of participating centers, blood and urine samples are collected preoperatively as well as directly postoperatively and on postoperative day 5. Samples will be analyzed centrally for systemic markers of inflammation and coagulation (including but not limited to interleukins 6 and 8, thrombin-antithrombin, protein C, and plasminogen activator inhibitor-1) as well as systemic markers of injury to the lungs (including but not limited to plasma E-cadherin, soluble receptor for advanced glycation end products, and surfactant proteins A and D) and to distal organs, including renal injury (including but not limited to plasma/urine neutrophil gelatinase-associated lipocalin and cystatin C). The standard operating procedure for collecting and processing biomarkers in plasma and urine is available in the online supplement (Additional files [4](#MOESM4){ref-type="media"} and [5](#MOESM5){ref-type="media"}, respectively).

Study visits and data collection {#Sec13}
--------------------------------

Patients are visited preoperatively, intraoperatively, daily between postoperative days 1 and 5, and at discharge. On postoperative day 90, patients are contacted by phone (Fig. [3](#Fig3){ref-type="fig"}). A complete participant time line, including all variables as well as interventions, is available in Additional files [1](#MOESM1){ref-type="media"} and [2](#MOESM2){ref-type="media"}.Fig. 3Schedule of enrollment, interventions, and assessments. *POD* Postoperative day, *PEEP* Positive end-expiratory airway pressure, *RM* Recruitment maneuver, *SpO* ~*2*~ Peripheral oxyhemoglobin saturation measured by pulse oximetry

During the preoperative visit, eligible patients meeting none of the exclusion criteria are asked by physicians to provide written informed consent. (Model consent form and information to study patients). Baseline variables are collected, including sex; age; height; weight; BMI; waist/hip ratio according to WHO guidelines; physical status according to the American Society of Anesthesiologists; functional status according to Cumulated Ambulation Score \[[@CR25]\]; cardiovascular status (heart failure according to the New York Heart Association classification, coronary heart disease according to Canadian Cardiovascular Society, atrial flutter/fibrillation, arterial hypertension); pulmonary status (COPD, including steroids and/or inhalation therapy use, respiratory infection within the last month, use of noninvasive ventilatory support); history of OSA, including apnea-hypopnea index or STOP-Bang score (snoring, tired, observed stopped breathing or choking/gasping, pressure, body mass index \>35 kg/m^2^, age \>50 years, large neck size, and male sex) \[[@CR26]\] in patients without diagnosis of OSA); metabolic status (diabetes mellitus, including data on treatment); history of active cancer; smoking status; alcohol status; gastroesophageal reflux; oral medication (e.g., use of antibiotics, statins, aspirin); preoperative organ function (SpO~2~ in beach chair position breathing room air; if possible, SpO~2~ in supine position breathing room air; if possible, so-called oxygen stress test, with this measurement left to the discretion of each center); respiratory rate; heart rate; mean arterial pressure; body temperature; airway secretion, including data on purulence, VAS score (1--10) for dyspnea, chest pain, and abdominal rest; and incident pain. Preoperative nonmandatory measurements include spirometry (forced ventilatory capacity, forced expiratory volume in 1 second), chest x-ray (assessed for infiltrates, pleural effusion, atelectasis, pneumothorax, and cardiopulmonary edema), and routine laboratory tests (including hemoglobin, white blood cell count, platelet count, prothrombin time, partial thromboplastin time, creatinine, blood urea nitrogen, alanine aminotransferase, aspartate amino transferase, bilirubin).

During the intraoperative visit, both surgery- and anesthesia-related data are recorded, including duration of surgery (from incision to closure), transfusion of blood products within 6 h before surgery, priority and type of surgery, wound classification, patient positioning during operation, duration of anesthesia (from intubation to extubation or exit from operating room if on mechanical ventilation), anesthetic procedure details, drugs and fluids administered during anesthesia (e.g., anesthetics, vasoactive drugs, transfusion). Ventilator settings, hemodynamics, need for rescue strategy, and AEs are recorded at anesthesia induction and hourly thereafter (in the higher PEEP group, before performing the RM) as well as during the plateau phase of the RM.

Clinical data, including actual organ function and the presence of PPCs and PEPCs, are scored during postoperative visits on a daily basis. Nonmandatory measures include chest x-ray, spirometry, and routine laboratory tests. Patients will be visited until discharge. On postoperative day 90, the sum of hospital-free days is recorded. Day 90 is defined as the last day of follow-up; accordingly, patients still admitted to the hospital will be last visited on that day.

Study dropouts {#Sec14}
--------------

Because participation in the trial is voluntary, a subject has the right to withdraw consent to participate in the study at any time for any reason without any consequences for further medical treatment. Furthermore, investigators have the right to terminate participation of any subject at any time if the investigator deems it in the participant's best interest. The reasons and circumstances for study discontinuation will be documented in the CRF. Primarily, all data will be analyzed according to the intention-to-treat (ITT) principle. Secondarily, data will be analyzed as per protocol.

Handling of data {#Sec15}
----------------

Patient data are collected in pseudonymous form using a patient identification number of six digits. The first three digits correspond to the site identifier, and the remaining three digits correspond to the patient inclusion number at the respective site. Study data are collected and managed using Research Electronic Data Capture (REDCap™; a web-based system used during PROBESE as electronic case report form) electronic data capture tools hosted at the Coordinating Center for Clinical Trials of the University of Dresden, Germany \[[@CR27]\]. REDCap is a Secure Sockets Layer (SSL)-encrypted, password-protected, web-based application designed to support data capture for research studies. Full access to the final trial dataset will be granted to selected investigators only (MGdA, TB, and JSc). If a substudy is approved by the steering committee, access to data related only to the substudy will be granted to the respective principal investigator.

Sample size calculations {#Sec16}
------------------------

Sample size calculation was based on our primary hypothesis that, in obese patients ventilated intraoperatively with protective low V~T~, high PEEP leads to lower incidence of PPCs than lower PEEP. Effect sizes were derived from data collected during the ARISCAT study \[[@CR13]\] and a single-center, relatively small study in which researchers reported the effects of intraoperative higher PEEP and RMs on the incidence of postoperative desaturation, chest infection, and bronchospasm in obese patients who underwent laparoscopic bariatric surgery \[[@CR28]\].

Prior to the start of the study, these calculations had indicated that 356 patients would be required per group, assuming a two-sided significance level of 0.05 (α) and a power of 80%, to detect the expected difference in PPCs between the higher-PEEP group of 30% and the lower-PEEP group of 40% (risk ratio of 0.75). However, the sample size was reestimated after data of the first 618 patients revealed that the overall incidence of the collapsed composite outcome was 20% and, thus, lower than initially expected. Also, the adjustment of the sample size took into account the need for interim analyses for efficacy and futility at 50%, 75%, and 100% of the total number of patients, for which a nonbinding group sequential design with γ spending functions (γ = −4 for each of α and β) was used. In total, 1912 patients will be included in the analysis. Assuming a dropout rate of 5%, 2013 patients will be enrolled. Table [3](#Tab3){ref-type="table"} shows the α and β spent over the trial, z-statistic boundaries for efficacy and futility, and boundary-crossing probabilities under the alternative hypothesis (H1). The corresponding *P* value boundaries for efficacy and futility at the first, second, and final looks, respectively, are *P* ≤ 0.006, *P* ≤ 0.015, and *P* ≤ 0.044, as well as *P* \> 0.82, *P* \> 0.35, and *P* \> 0.044, respectively. Figure [4](#Fig4){ref-type="fig"} displays the z-statistic boundaries for efficacy/harm and futility as a function of accrued sample size. East 6.0 interim monitoring software (Cytel Inc., Cambridge, MA, USA) was used for sample size calculations.Table 3Z-statistic boundaries and boundary-crossing probabilitiesLookInformation fraction*N*Cumulative α spentCumulative β spentZ-efficacyZ-futilityBoundary-crossing probabilities under H1EfficacyFutility10.59560.0060.024≥2.75\<0.2250.2340.02420.7514340.0180.071≥2.432\<0.9290.2960.0473119120.050.2≥2.012\<2.0120.2710.129*Look* Interim analysis, *N* Number of patients, *H1* Hypothesis 1 (group difference exists)Values were calculated using power = 0.80, α = 0.05, γ spending functions (γ = −4), and expected incidence of postoperative pulmonary complications of 20% (p1) and 15% (p2) in the lower and higher positive end-expiratory pressure groups, respectively Fig. 4Effect size (Z) according to enrollment of patients in the PRotective Ventilation with Higher versus Lower PEEP during General Anesthesia for Surgery in OBESE Patients (PROBESE) trial

To foster the study and increase the interest of practicing physicians, the steering committee will apply for endorsement of national and international professional societies. The following societies have already given endorsement to the trial: the European Society of Anaesthesiology, the European Society for Perioperative Care of the Obese Patient, the German Society of Anesthesiology and Intensive Care Medicine, and the Italian Society of Anesthesiology and Reanimation.

Statistical analysis {#Sec17}
--------------------

Exploratory analysis will include mean and SD for normally distributed variables. Non-normally distributed variables will be expressed by their medians and IQRs, and categorical variables will be expressed as count (percent). Parametric or nonparametric tests will be used as appropriate. Categorical variables will be compared with chi-square tests, Fisher's exact test, or as relative risk, if appropriate. Statistical uncertainty will be expressed by 95% CIs.

Preoperative (baseline) data will be tested for any imbalance. If imbalances are detected (despite 1:1 randomization of a relatively large cohort), those factors will be corrected for using a multiple logistic regression model.

The primary endpoint, namely occurrence of any PPC (collapsed composite endpoint) within the first 5 postoperative days, will be presented as total percentage per group and analyzed as continuous data. Primary and secondary outcome variables describing time to event will be analyzed using a proportional hazards model adjusted for possible baseline imbalances. A linear mixed model with two factors (study group and time) will be used to analyze variables repetitively measured over time.

In case of loss to follow-up or study dropout, those cases will be reported, and ITT as well as per-protocol analyses will be performed. For ITT analysis, data will be processed for all patients in the groups to which they were randomized. The per-protocol analysis will be conducted to assess the primary outcome in cases where there is a considerable proportion of patients who do not receive their randomized intervention or are lost to follow-up. Patients discharged earlier than postoperative day 5 are considered as not experiencing any PPC or PEPC during the out-of-hospital days. In this regard, missing data will be handled by means of the last observation carried forward method.

Given that laparoscopic surgery is common in obese patients, we anticipate that a subgroup analysis of primary and secondary endpoints will be conducted for this type of surgery as well. A further subgroup analysis of patients with obesity class III according to the WHO definition (i.e., BMI ≥40 kg/m^2^) will be performed. Given the importance of driving pressure to determine PPCs \[[@CR29], [@CR30]\], a subgroup analysis taking into account cutoff values and changes in PEEP will be conducted.

Possibility and policy for substudies {#Sec18}
-------------------------------------

Participating centers are allowed to conduct substudies, provided that (1) no interference with the primary protocol occurs; (2) approval by the local institutional review board is obtained; and (3) the steering committee accepts the proposal according to its originality, feasibility, and importance. Currently, substudies with electrical impedance tomography, spirometry, respiratory system mechanics, and preoperative oxygen stress test are under evaluation. Publication of substudies, in any form, is strictly forbidden until the results of the primary study have been published.

Trial organization {#Sec19}
------------------

The trial is managed by a team consisting of the chief investigator (MGdA), the trial coordinator (TB), the statisticians (JSc, GM), the informatics technician responsible for the web-based electronic data capture system (Marko Kaeppler), and the monitors (Luigi Vivona, Alice Bergamaschi). A steering committee contributed to the design and revision of the study and will be responsible for interpretation of data and compilation of a resulting manuscript.

Patient data and safety are closely monitored by a DSMB, which is composed of a chairperson (Daniel Sessler) and four other members (Jennifer Hunter, Jeanine Wiener-Kronish, Jean-Louis Vincent, and Andreas Hoeft). All AEs entered into the electronic CRF within prespecified time frames, including severe AEs and suspected unexpected severe adverse reactions, are monitored by an international AE manager (ASN), who provides the DSMB with reports for review. The DSMB further monitors the overall status of the trial (e.g., progress of patient enrollment, general adherence to protocol, and completeness of data entry). Monitoring visits will be conducted as deemed necessary by the DSMB. National coordinators are responsible for administration and communication with local principal investigators, as well as for assistance during trial management and data collection. When submitting the report on the results of the trial for possible publication, sites will be eligible for one collaborative coauthorship plus a further coauthorship for every 12 treated patients with complete datasets.

Discussion {#Sec20}
==========

Despite being lifesaving, mechanical ventilation has the potential to aggravate or even initiate lung injury. In patients with previously injured lungs, especially those with ARDS, mechanical ventilation with low V~T~ \[[@CR31]\] and driving pressures \[[@CR32]\] has been shown to decrease mortality. Furthermore, in more severe ARDS, high PEEP improves survival \[[@CR33]\]. Such effects have been attributed to avoidance of tidal overdistention as well as cyclic collapse and reopening of lung units, which may trigger the inflammatory lung response \[[@CR34]\]. Interestingly, low V~T~ with low to moderate PEEP levels has been also reported to facilitate weaning \[[@CR35]\] and reduce pulmonary complications \[[@CR36]\] in critically ill patients without lung injury. However, the value of protective ventilation in the absence of lung injury has been challenged. In pigs with noninjured lungs, V~T~ as high as 27 ml/kg was not associated with relevant degrees of lung damage \[[@CR37]\]. Such an observation might be explained by the fact that, within a certain range, mechanical ventilation does not injure lungs if a previous insult (first hit), such as inflammation, ischemia-reperfusion injury, or factors impairing the homogeneity of ventilation \[[@CR38]\], are not present. Surgery itself can trigger a systemic inflammatory response \[[@CR39]\], which may prime the lungs for possible harmful effects of mechanical ventilation. In fact, protective intraoperative mechanical ventilation with low V~T~ and PEEP is able to prevent postoperative respiratory failure in patients undergoing abdominal or thoracic surgery, and those who develop this adverse pulmonary event not only have longer stays in the hospital but also a significantly higher risk of death \[[@CR2]\]. However, though the role of intraoperative low V~T~ \[[@CR6]\] and low driving pressure \[[@CR29], [@CR30]\] to decrease the risk of PPCs has been defined, the role of PEEP is more controversial \[[@CR4], [@CR7], [@CR40], [@CR41]\].

The decision to address the obese patient population undergoing surgery is based on several aspects. The proportion of obese patients undergoing surgery is higher than in the general population \[[@CR42]\]. Treatment of these patients is usually challenging because their needs in terms of perioperative care differ from those of nonobese patients and are often unmet. For example, the deleterious effects of anesthesia on the respiratory system of obese patients are exacerbated when compared with nonobese patients. The known decrease in end-expiratory lung volume following induction of general anesthesia is striking in obese patients, mainly because of formation of lung atelectasis, which may impair gas exchange \[[@CR43]\]. Previous studies addressed the effects of intraoperative mechanical ventilation strategies aimed at reverting the formation of atelectasis during general anesthesia in obese patients. Respiratory strategies that increase the pressure of the airways during induction of anesthesia, such as the application of noninvasive ventilation \[[@CR44]\], use of PEEP with \[[@CR45]\] or without RMs \[[@CR46]\], or a combination of all of these \[[@CR47]\], seem to be useful for improving the respiratory function of obese patients in the pre- and intraoperative periods \[[@CR48]\]. Nevertheless, their effects seem to be short-lived in the postoperative period \[[@CR49], [@CR50]\]. To our knowledge, the impact of such strategies on clinically relevant outcome endpoints, such as adverse pulmonary events, has not previously been addressed. Therefore, we believe PROBESE is the first large, international, multicenter randomized controlled trial addressing the effects of PEEP during protective low V~T~ on postoperative outcome.

We opted for testing the impact of two ventilation strategies at the same low V~T~ but mainly differing in the level of PEEP. The decision to use a PEEP value of 4 cmH~2~O in the low-PEEP group derives mainly from reports on the practice of intraoperative mechanical ventilation in obese patients \[[@CR11], [@CR51]\], but it also takes into account aspects regarding patient safety. In fact, use of PEEP of 0 cmH~2~O during anesthesia in morbidly obese patients is still common practice and is usually compensated for by means of proportionally high V~T~ values \[[@CR52]\]. The level of PEEP in the high-PEEP group has been intensely debated by the steering committee of the trial. The decision to use a PEEP of 12 cmH~2~O was based on reports of several small clinical studies showing that such a level of PEEP is able to preserve the end-expiratory lung volume after induction of anesthesia \[[@CR46], [@CR53]\] and to avoid development of significant atelectasis when preceded by RMs \[[@CR45]\]. Theoretically, PEEP values \>12 cmH~2~O might be even more effective to avoid progressive derecruitment of lungs, but they could also result in more severe impairment of hemodynamics \[[@CR54], [@CR55]\]. In fact, a previous trial by our group with nonobese patients undergoing open abdominal surgery showed that high PEEP levels are more frequently associated with intraoperative hypotension that in turn requires more fluids and support with vasoactive drugs \[[@CR7]\]. We also decided not to use an individual titration of PEEP for two reasons. First, even a PEEP titrated to a respiratory mechanical target, such as the elastance of the respiratory system, represents a compromise in terms of regional overdistention and collapsing-reopening of lung units and does not fully prevent atelectasis formation. Second, the setting of PEEP shall be pragmatic (i.e., practicable for anesthetists worldwide) while keeping the physiological rationale. The RM is based on a stepwise increase of V~T~ and PEEP, which allows opening of lung units without interruption of mechanical ventilation \[[@CR40]\] and ensures standardization across different centers \[[@CR7]\]. Furthermore, because the maneuver was designed for volume-controlled ventilation, it can be performed with practically all anesthesia ventilators. During RMs, the target airway pressure in the range of 40--50 cmH~2~O was based on previous functional studies in obese patients. Also, the inspiratory time of approximately 5 seconds was chosen to allow enough pressure versus time product to open atelectatic lung units \[[@CR56]\]. We opted for recruiting lungs not only after intubation but also every hour thereafter in order to revert possible progressive derecruitment at PEEP of 12 cmH~2~O. For both the lower- and higher-PEEP groups, rescue protocols for the progression of intraoperative hypoxemia were defined to protect patients while allowing a standardized approach that minimizes interference with the respective interventions. Importantly, deviations from the protocol, even rescue because of hypoxemia, are explicitly allowed, provided this is in the best interest of the patient.

It is worth noting that recommendations have been made also with regard to different phases and aspects of the anesthetic procedure, including monitoring, choice of anesthetic agents, muscle paralysis and its reversal, intravascular volume loading and maintenance, postoperative analgesia target, and respiratory management at induction and emergence of anesthesia (e.g., use of continuous or noninvasive positive pressure and positioning). However, PROBESE is a pragmatic study, and influence on local practice of respective sites is being kept to a minimum, focusing on factors that are more directly related to the hypothesis being investigated.

Besides postoperative respiratory failure, several other adverse pulmonary events seem to add to the odds of mortality in the surgical population. In-hospital length of stay and mortality increase with the number of single pulmonary AEs in the postoperative period \[[@CR1]\]. For this reason, in the PROBESE trial, we opted for a binary collapsed composite of single adverse pulmonary events as a primary endpoint, despite the fact that single events may differ in terms of severity. Therefore, the use of PPCs as a primary endpoint in the PROBESE trial not only has clinical relevance for the practicing anesthetist but also increases the study power because of summation of the incidence of single AEs. In spite of this, the study analysis will address not only the composite itself but also the incidence of each element separately, as well as a secondary composite that excludes mild respiratory failure. Furthermore, given the importance of minimally invasive surgical techniques in the obese population, we will conduct a separate analysis of the primary endpoint in patients undergoing laparoscopic surgery, as well as of patients with obesity class III of the WHO (BMI ≥40 kg/m^2^).

Not only the respiratory system but also other organ systems may be impaired in the postoperative period in obese patients. Thus, the analysis will also address the impact of intraoperative mechanical ventilation on single organs and a collapsed composite of nonpulmonary AEs, namely the PEPCs. In addition, further relevant outcome measures that might be related to PPCs and PEPCs, especially the length of hospital stay, will be addressed. This outcome variable not only is a measure of morbidity but has also direct impact on related health costs. Because we anticipate that, during surgery, both the lower- and the higher-PEEP groups will experience impacts on intraoperative oxygenation, respiratory system mechanics, and arterial blood pressure, intraoperative respiratory function and hemodynamic variables will also be evaluated.

Much attention has been paid to safety in the PROBESE trial. Accordingly, data and patient safety during the PROBESE trial is closely monitored by a DSMB whose members have been chosen for their expertise in clinical research, as well as by a serious AE/AE manager. The web-based approach for research electronic data capture (REDCap™) will be used for building the database within a secure system and allowing access to the electronic CRF as well as randomization of patients into groups within one single platform from all participating sites across the world.

In summary, PROBESE is the first multicenter, international, adequately powered randomized controlled trial that compares the effects of two different levels of intraoperative PEEP during protective low V~T~ on PPCs in obese patients. The results of the PROBESE trial will support anesthesiologists in their decision to set PEEP during general anesthesia for surgery in obese patients.

Trial status {#Sec21}
------------

The PROBESE trial is currently recruiting patients.

Additional files {#Sec24}
----------------

Additional file 1:PROBESE Study protocol version 2.5. This PDF file includes the most recent version of the PROBESE Study protocol with changes highlighted. (PDF 870 kb) Additional file 2:Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 checklist: recommended items to address in a clinical trial protocol and related documents. (PDF 122 kb). Additional file 3:PROBESE case report form version 1.2.2. This file corresponds to the paper version of the case report form. (DOC 1610 kb). Additional file 4:Standard operating procedures (SOP) for plasma Sampling. (PDF 115 kb) Additional file 5:Standard operating procedures (SOP) for plasma Sampling. (PDF 110 kb)
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AE

:   Adverse event

ARDS

:   Acute respiratory distress syndrome

ARISCAT

:   Assess Respiratory Risk in Surgical Patients in Catalonia

BMI

:   Body mass index

CONSORT

:   Consolidated Standards of Reporting Trials

COPD

:   Chronic obstructive pulmonary disease

CRF

:   Case report form

DIC

:   Disseminated intravascular coagulation

DSMB

:   Data and Safety Monitoring Board

FiO~2~

:   Fraction of inspired oxygen

GIF

:   Gastrointestinal failure

I:E

:   Inspiratory-to-expiratory ratio

ICU

:   Intensive care unit

INR

:   International normalized ratio

ITT

:   Intention-to-treat

OSA

:   Obstructive sleep apnea

PaO~2~

:   Partial pressure of arterial oxygen

PBW

:   Predicted body weight

PEEP

:   Positive end-expiratory pressure

PEPC

:   Postoperative extrapulmonary complication

POD

:   Postoperative day

PPC

:   Postoperative pulmonary complication

Ppeak

:   Peak airway pressure

Pplat

:   Plateau airway pressure

PROBESE trial

:   PRotective Ventilation with Higher versus Lower PEEP during General Anesthesia for Surgery in OBESE Patients

REDCap™

:   Research Electronic Data Capture (web-based system used during PROBESE as electronic case report form)

RIFLE classification system

:   Risk, injury, failure, loss, end-stage kidney disease

RM

:   Recruitment maneuver

RR

:   Respiratory rate

SPIRIT

:   Standard Protocol Items: Recommendations for Interventional Trials

SpO~2~

:   Peripheral oxyhemoglobin saturation measured by pulse oximetry

SSL

:   Secure Sockets Layer

VAS

:   Visual analogue scale

V~T~

:   Tidal volume

WHO

:   World Health Organization
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